Pulse Biosciences grants CFO 300,000 stock options
PULSE BIOSCIENCES, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Financial Officer Jon Skinner received a grant of stock options for 300,000 shares of common stock on February 3, 2025. The options have an exercise price of $20.93 per share and expire on February 3, 2035. Half of the options vest in equal installments over four years, and the remaining half vest in tranches tied to performance goals based on the company’s market capitalization between $2 billion and $5 billion and GAAP revenue targets between $48 million and $175 million, subject to his continued service.
Insider Trade Summary
Grant/Award: 300,000 shares
Grant/Award
1 txn
Insider
Skinner Jon
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 300,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 300,000 contracts (Direct)
Footnotes (1)
- F1. Half of the shares subject to the option will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date and the remaining shares subject to the option will vest in equal tranches upon the achievement of four performance-based vesting criteria tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion and GAAP revenue targets ranging from $48 million to $175 million, in all cases, subject to the Reporting Person's continued service through each vesting milestone.
Key Figures
Option Shares Granted: 300,000 shares
Exercise Price: $20.93 per share
Underlying Common Shares: 300,000 shares
+3 more
6 metrics
Option Shares Granted
300,000 shares
Stock Option (right to buy) granted to CFO Jon Skinner on February 3, 2025
Exercise Price
$20.93 per share
Conversion or exercise price for the 300,000 stock options
Underlying Common Shares
300,000 shares
Common Stock underlying the Stock Option (right to buy)
Option Expiration Date
February 3, 2035
Expiration date of the Stock Option granted to Jon Skinner
Market Capitalization Targets
$2 billion to $5 billion
Performance-based vesting criteria for a portion of the option
GAAP Revenue Targets
$48 million to $175 million
Performance-based vesting criteria for a portion of the option
Key Terms
Stock Option (right to buy), GAAP revenue, market capitalization, performance-based vesting criteria
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
GAAP revenue financial
"and GAAP revenue targets ranging from $48 million to $175 million"
GAAP revenue is the sales a company reports using U.S. Generally Accepted Accounting Principles, the standardized rules that determine when and how income from goods or services is recorded. Investors use GAAP revenue as a consistent, comparable measure of a company’s top-line performance—like measuring different objects with the same ruler—so they can spot true growth, compare firms, and evaluate whether sales figures reflect ongoing business activity or accounting timing.
market capitalization financial
"tied to both the Issuer's market capitalization ranging from $2 billion to $5 billion"
Market capitalization is the total market value of a company’s outstanding shares, calculated by multiplying the current share price by the number of shares issued. It gives a quick snapshot of a company’s size and how investors value it, influencing perceived risk, index membership, and roughly how much it might cost to buy the whole company — like using a sticker price to compare the relative size and price of different houses.
performance-based vesting criteria financial
"will vest in equal tranches upon the achievement of four performance-based vesting criteria"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PLSE disclose for Jon Skinner?
PLSE disclosed that Chief Financial Officer Jon Skinner received a grant of stock options for 300,000 shares of common stock on February 3, 2025, with an exercise price of $20.93 per share and an expiration date of February 3, 2035.
What is the exercise price of Jon Skinner’s new PLSE stock options?
The stock options granted to Jon Skinner have an exercise price of $20.93 per share, allowing him to purchase up to 300,000 shares of Pulse Biosciences, Inc. common stock at that price if the options vest and are exercised before expiration.
How do Jon Skinner’s PLSE options vest over time and performance?
Half of the option shares vest in equal installments on the first, second, third, and fourth anniversaries of the grant date. The remaining half vests in equal tranches upon achieving market capitalization targets between $2 billion and $5 billion and GAAP revenue targets between $48 million and $175 million.
What performance metrics affect vesting of PLSE options granted to Jon Skinner?
The performance-based portion of Jon Skinner’s options vests upon achievement of four criteria tied to PULSE BIOSCIENCES, INC.’s market capitalization ranging from $2 billion to $5 billion and GAAP revenue targets ranging from $48 million to $175 million, with continued service required.
When do Jon Skinner’s PLSE stock options expire?
Jon Skinner’s stock options in PLSE expire on February 3, 2035. He may exercise up to 300,000 options at an exercise price of $20.93 per share, subject to the time-based and performance-based vesting conditions and his continued service.
Is Jon Skinner’s PLSE option grant a purchase or a compensation award?
The Form 4 describes the transaction as a grant or award acquisition of a Stock Option (right to buy) for 300,000 shares, coded as an A transaction, indicating it is a compensation-related award rather than a market purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
